Actively Recruiting
Evaluation of T-bren Versus Platinum-Based Chemotherapy for HER2-Expressing Metastatic Urothelial Cancer After Anti-PD-L1 Therapy Progression
Led by SystImmune Inc. · Updated on 2026-10-13
520
Participants Needed
2
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of T-bren in adults with HER2-expressing metastatic urothelial cancer who have experienced disease progression during or after anti-PD-L1-based therapy. This global Phase 3 study compares T-bren to standard platinum-based chemotherapy to understand which treatment better controls the cancer. Participants are randomly assigned to receive one of the two intravenous doses of T-bren every 21 days or a combination of gemcitabine plus either cisplatin or carboplatin chemotherapy given intravenously on specific days during 21-day cycles. The study includes a treatment phase and follows participants for approximately five years to monitor outcomes. During the study, participants undergo regular assessments including tumor measurements based on RECIST criteria, evaluations of progression-free survival, overall survival, and response rates. Safety is closely monitored by tracking adverse and serious adverse events. The study requires fresh or archival tumor samples and evaluates HER2 expression. Participation lasts for up to about five years, including treatment and follow-up periods.
CONDITIONS
Brief Title
BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy
Research Team
C
Christine LaRock
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here